leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...2526272829303132333435...235236»
  • ||||||||||  leucovorin calcium / Generic mfg.
    Journal:  A new mathematical model of folate homeostasis in E. coli highlights the potential importance of the futile cycle of folinic acid in cell growth. (Pubmed Central) -  Jan 15, 2024   
    Model simulations revealed: 1) the folate cycle behaved as a stable biochemical system in three growth states (slow, standard, and rapid); 2) the initial concentration of serine had the greatest impact on metabolite concentrations; 3) 5-formyltetrahydrofolate cyclo-ligase (5-FCL) activity had a significant impact on the levels of the 7 products that carry the one-carbon donated from folates, and the redox couple NADP/NADPH; this was particularly evident in the rapid growth state; 4) 5-FCL may be vital to the survival of the cells by maintaining low levels of homocysteine, as high levels can induce toxicity; and 5) the antifolate therapeutic trimethoprim had a greater impact on folate metabolism with higher nutrient availability. These results highlight the important role of 5-FCL in intracellular folate homeostasis and mass generation under different metabolic scenarios.
  • ||||||||||  leucovorin calcium / Generic mfg.
    A Case with Cobalamin-C-Deficiency and Severe Heart Failure Resolved by LVAD Implantation and Subsequent Heart Transplantation (Board #274; Poster Hall) -  Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1767;    
    Severe congestive heart failure (HF) may also occur with a poorly documented clinical course.Case Report The index case was diagnosed at the age of 3 days with cblC deficiency caused by homozygosity of the C331T mutation in the MMACHC gene, and medically managed with OH-Cbl, mecobalamine, carnitine, betaine, and calcium folinate...At the latest clinic visit, one year after HTx, the patient was markedly improved.Summary To the best of our knowledge, this is the first ever reported case of a patient with cblC deficiency undergoing an LVAD implantation and subsequently a HTx. Although both interventions were complicated with bleeding events, surgical management and transplantation can be needed to treat advanced HF in cblC deficiency.
  • ||||||||||  TTX-080 / Tizona Therap
    Phase classification, Monotherapy:  TTX-080-001: TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers (clinicaltrials.gov) -  Jan 9, 2024   
    P1,  N=240, Active, not recruiting, 
    Although both interventions were complicated with bleeding events, surgical management and transplantation can be needed to treat advanced HF in cblC deficiency. Phase classification: P1a/1b --> P1
  • ||||||||||  ondansetron / Generic mfg.
    Enrollment closed, Enrollment change:  OPT-JIA: The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis (clinicaltrials.gov) -  Jan 9, 2024   
    P=N/A,  N=52, Active, not recruiting, 
    The rate of germline BRCA1 and BRCA2 mutations found in patients with unresectable pancreatic cancer was comparable to those of previous studies.An analysis of germline BRCA1 and BRCA2 mutations has benefits for all patients with unresectable pancreatic cancer with regard to decisions on therapeutic strategies in a clinical practice setting. Recruiting --> Active, not recruiting | N=176 --> 52
  • ||||||||||  Fruzaqla (fruquintinib) / Takeda
    Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 8, 2024   
    P1/2,  N=46, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Koselugo (selumetinib) / Merck (MSD), AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Enrollment closed, Metastases:  MAZEPPA: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. (clinicaltrials.gov) -  Jan 5, 2024   
    P2,  N=307, Active, not recruiting, 
    Additionally, completion of adjuvant chemotherapy could be helpful to patients who undergo neoadjuvant chemotherapy regardless of their response to neoadjuvant chemotherapy. Recruiting --> Active, not recruiting
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma. (Pubmed Central) -  Jan 3, 2024   
    In patients with non-metastatic pancreatic ductal adenocarcinoma who underwent neoadjuvant therapy, tumor size reduction was a significant predictor of resectability and pathologic response, including complete and near complete responses, whereas serum carbohydrate antigen 19-9 normalization predicted resectability, disease recurrence, and survival. Patients with a postoperative carbohydrate antigen 19-9 rise after prior normalization after administration of neoadjuvant therapy were at an increased risk of recurrence and worse overall survival.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Opdivo (nivolumab) / Ono Pharma, BMS
    MODULE 1: Recent Developments in the Management of Localized/Locally Advanced Gastroesophageal Cancers (Golden Gate Ballroom ) -  Jan 2, 2024 - Abstract #ASCOGI2024ASCO_GI_904;    
    This activity is supported by educational grants from Astellas, BeiGene Ltd, Bristol Myers Squibb, and Lilly. Early data with immune checkpoint inhibitors as neoadjuvant therapy for resectable microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) gastric/gastroesophageal junction (GEJ) adenocarcinoma Design, eligibility criteria and primary and second endpoints of the Phase III MATTERHORN study of neoadjuvant durvalumab and fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) chemotherapy followed by adjuvant durvalumab for patients with resectable gastric/GEJ cancer Emerging data from MATTERHORN showing a statistically significant improvement in pathologic complete response rate with the addition of durvalumab to neoadjuvant FLOT versus neoadjuvant FLOT alone; potential implications for disease management paradigms Key efficacy and safety outcomes from the Phase III CheckMate 577 trial evaluating adjuvant nivolumab for patients with esophageal or GEJ cancers after neoadjuvant chemoradiation therapy and surgery FDA approval and appropriate identification of patients for adjuvant nivolumab Ongoing Phase III studies evaluating neoadjuvant and/or adjuvant immune checkpoint inhibitors for patients with localized/locally advanced gastroesophageal cancers